ALNY icon

Alnylam Pharmaceuticals
ALNY

Overview Fund Activity
461.14 USD
-4.75
1.02%
At close Updated Sep 15, 4:00 PM EDT
Pre-market
After hours
461.14
0.00
0%
1 day
-1.02%
5 days
0%
1 month
2.72%
3 months
49.34%
6 months
82.19%
Year to date
97.39%
1 year
70.56%
5 years
253.34%
10 years
327.97%
 

About: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Employees: 2,230

Healthcare Biotechnology
0
Funds holding %
of 7,463 funds
0
Analysts bullish %
of 20 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

56% more first-time investments, than exits

New positions opened: 97 | Existing positions closed: 62

26% more capital invested

Capital invested by funds: $34.2B [Q1] → $43B (+$8.8B) [Q2]

20% more repeat investments, than reductions

Existing positions increased: 257 | Existing positions reduced: 214

5% more funds holding

Funds holding: 617 [Q1] → 646 (+29) [Q2]

3.42% more ownership

Funds ownership: 97.8% [Q1] → 101.22% (+3.42%) [Q2]

8% less call options, than puts

Call options by funds: $188M | Put options by funds: $203M

10% less funds holding in top 10

Funds holding in top 10: 10 [Q1] → 9 (-1) [Q2]

See Fund Rankings

Research analyst outlook

20 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$359
22% downside
Avg. target
$461
0% upside
High target
$583
26% upside

20 analyst ratings

18  positive
90%
2  neutral
10%
0  negative
0%
Evercore ISI Group
Liisa Bayko
$515
Outperform
Maintained
11 Sep 2025
BMO Capital
Kostas Biliouris
$470
Outperform
Maintained
8 Sep 2025
HC Wainwright & Co.
Patrick R. Trucchio
$570
Buy
Reiterated
2 Sep 2025
Citigroup
David Lebovitz
$583
Buy
Maintained
2 Sep 2025
HC Wainwright & Co.
Patrick Trucchio
$570
Buy
Maintained
7 Aug 2025
See Analyst Rankings

Financial journalist opinion

Based on 15 articles about ALNY published over the past 30 days

Neutral
Seeking Alpha
5 days ago
Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 12:20 PM EDT Company Participants Jeffrey Poulton - CFO & Executive VP Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Positive
Zacks Investment Research
5 days ago
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains?
Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains?
Neutral
Business Wire
6 days ago
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The size of the offering was increa.
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
Neutral
Business Wire
7 days ago
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with this offering, Alnylam expects to gran.
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
Positive
Zacks Investment Research
7 days ago
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
Alnylam's strong drug sales and advancing partnerships with Regeneron and Roche highlight key growth drivers in the quarters ahead.
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
Neutral
Seeking Alpha
12 days ago
Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Citi's Biopharma Back to School Conference September 3, 2025 1:45 PM EDT Company Participants Jeffrey Poulton - CFO & Executive VP Kevin Fitzgerald - Executive VP, Chief Scientific Officer and Head of Early Research & Early Development Conference Call Participants David Lebowitz - Citigroup Inc., Research Division Presentation David Lebowitz Research Analyst Thank you all. Welcome all again to the 2025 Citi Biopharma Conference in Boston.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript
Positive
Seeking Alpha
13 days ago
Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives
Alnylam's strong clinical productivity and commercial execution continue to support my view that it's one of the best all-around biotechs, with a robust revenue and earnings outlook. Amvuttra's TTR-CM launch has exceeded initial expectations, driving significant revenue growth and reinforcing its long-term potential in the TTR space. While KARDIA-3 results for zilebesiran were mixed, the drug still holds multibillion-dollar potential, and Alnylam's pipeline remains deep and promising.
Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives
Positive
Zacks Investment Research
14 days ago
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
Neutral
Business Wire
15 days ago
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral sess.
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM
Neutral
Business Wire
16 days ago
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardiovascular outcomes trial (CVOT) to evaluate the ability of zilebesiran, an RNAi therapeutic, to reduce the risk of major adverse cardiovascular events in patients with uncontrolled hypertension. This decision was informed by the comprehensive KARDIA Phase II program, including KARDIA-1, KARDIA-2 and.
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
See News Rankings
Charts implemented using Lightweight Charts™